Loading
A phase 2 trial of Glofitamab, Tocilizumab, Doxorubicin, Vincristine, Prednisone and Rituximab in non-Hodgkin lymphoma, run by Hoffmann-La Roche, active and no longer recruiting.
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma is a phase 2 interventional study registered as NCT04980222 by Hoffmann-La Roche, with 46 participants enrolled, started 2022-03-22 and due to reach its primary completion in 2024-09-24. Interventions recorded: Glofitamab, Tocilizumab, Doxorubicin, Vincristine, Prednisone and Rituximab. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
46 enrolled.
95% CI 58.06 to 85.40; Figures from the ClinicalTrials.gov results section (first posted 2026-08-18), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| End of Treatment Complete Response (EOT CR) Rateprimary | Glofitamab + R-CHOP Immunochemotherapy | 45 | 73.3% | - | - | link |
Shares Tocilizumab, Glofitamab, Flatiron Health (Roche), Rituximab and the tag pipeline.
Shares Tocilizumab, Glofitamab, Flatiron Health (Roche), T-cell engagers (bispecific) and the tag pipeline.
Shares Prednisone, Rituximab, Doxorubicin, Monoclonal antibodies and the tag pipeline.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin and the tag pipeline.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin and the tag pipeline.
Shares Prednisone, Rituximab, Doxorubicin, Monoclonal antibodies and the tag pipeline.
Shares Glofitamab, Flatiron Health (Roche), T-cell engagers (bispecific), Cytotoxic chemotherapy and the tag pipeline.
Shares Prednisone, Vincristine, Rituximab, Doxorubicin and the tag pipeline.